Welcome to our dedicated page for Organigram Global SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organigram Holdings Inc’s multi-tiered grow rooms may be spotless, but its SEC disclosures can feel like a jungle of biological-asset valuations and shifting cannabis regulations. Investors hunting for yield forecasts, segment revenue by brands like SHRED or Edison, or a trace of insider selling know that one 10-K can top 300 pages.
Stock Titan clears the path. Our AI reviews every document the minute it hits EDGAR, translating technical notes into plain language and flagging what moves markets. Get Organigram Holdings Inc insider trading Form 4 transactions in real time, compare cultivation costs in the Organigram Holdings Inc quarterly earnings report 10-Q filing, and see risk-factor changes highlighted automatically. Even sudden product-recall updates in an 8-K are summarized before the smoke clears.
- Organigram Holdings Inc Form 4 insider transactions real-time—custom alerts on executive moves
- Organigram Holdings Inc annual report 10-K simplified—cash burn, biological asset gains, capital plans
- Organigram Holdings Inc proxy statement executive compensation distilled into clear tables
- Organigram Holdings Inc 8-K material events explained with cannabis-sector context
- Organigram Holdings Inc earnings report filing analysis for brand-level growth trends
Use the platform to monitor executive stock transactions Form 4 before material events, satisfy auditors asking for “Organigram Holdings Inc SEC filings explained simply,” or tackle complex questions like “understanding Organigram Holdings Inc SEC documents with AI.” No more forensic reading—just precise insights delivered the moment you need them.
Organigram Global Inc., a Canadian cannabis company listed on the TSX and Nasdaq under the symbol “OGI”, filed its annual report on Form 40-F as a foreign private issuer using IFRS.
The report notes 134,461,029 common shares outstanding as of the fiscal year ended September 30, 2025 and incorporates audited consolidated financial statements, management’s discussion and analysis, and an annual information form by reference.
Management determined that the company’s disclosure controls and internal control over financial reporting were not effective as of September 30, 2025 because of material weaknesses, and the independent auditor issued an adverse opinion on the effectiveness of ICFR.
The filing outlines remediation steps completed in Q4 Fiscal 2025, including engaging internal control specialists, hiring a VP of Information Technology, dedicating resources to review third‑party service organization reports and remediating certain IT general controls, and describes the board’s independent audit, compensation, governance and investment committees, code of ethics and alignment with TSX and applicable Nasdaq corporate governance standards.
FAQ
What is the current stock price of Organigram Global (OGI)?
What is the market cap of Organigram Global (OGI)?
